Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (Baiyunshan Pharma) filed its Monthly Return for Equity Issuer for the period ended 31 August 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised / Registered Capital • Total authorised share capital stood at RMB 1.63 billion, comprising: – 219.90 million H shares listed in Hong Kong, each with a par value of RMB 1. – 1.41 billion A shares listed on the Shanghai Stock Exchange, each with a par value of RMB 1.

Issued Shares and Public Float • Issued H shares: 219.90 million; issued A shares: 1.41 billion. • The company held no treasury shares, and there were no increases or decreases in either class during August. • Baiyunshan Pharma confirmed compliance with the Main Board public-float requirement, maintaining at least 5% of H-share free float.

Capital Instruments • No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding.

Corporate Governance Confirmation • The filing, signed by Company Secretary Huang Xuezhen on 1 September 2026, states that all regulatory and listing-rule obligations associated with the company’s share capital have been duly met.

The unchanged capital structure underscores operational stability, with the company entering September 2026 carrying the same equity base recorded at end-July.